Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
SKYE
SKYE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest SKYE ETF News Today | Earnings, Events & Price Alerts
SKYE News
Skye Bioscience Reports Interim Data from Nimacimab Study
Feb 02 2026
Benzinga
Skye Bioscience Reports Positive Clinical Data from Nimacimab Study
Feb 02 2026
NASDAQ.COM
Skye Bioscience to Present Nimacimab Efficacy Study at Keystone Conference
Jan 21 2026
Newsfilter
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Join
Jan 19 2026
PRnewswire
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Claim
Jan 19 2026
PRnewswire
Skye Bioscience, Inc. Class Action Reminder: Lead Plaintiff Deadline January 16, 2026
Jan 16 2026
PRnewswire
Skye Bioscience Faces Class Action Lawsuit with Claims Deadline of January 16, 2026
Jan 16 2026
Globenewswire
Skye Bioscience Class Action Launched, Lead Plaintiff Deadline January 16
Jan 15 2026
Globenewswire
Skye Bioscience Faces Class Action Over Misleading Statements, Stock Plummets 60%
Jan 15 2026
Globenewswire
Skye Bioscience (NASDAQ:SKYE) Faces Class Action Allegations of Misleading Statements
Jan 15 2026
PRnewswire
Skye Bioscience (SKYE) Faces Allegations of Misleading Statements; Shareholders Encouraged to Join Class Action
Jan 15 2026
Globenewswire
Skye Bioscience Faces Class Action for Securities Fraud; Investors Can Join by Jan 16, 2026
Jan 14 2026
Globenewswire
Faruqi & Faruqi Encourages Skye Investors to Discuss Legal Options
Jan 14 2026
Globenewswire
Skye Bioscience Faces Class Action Lawsuit with Deadline for Claims by January 16, 2026
Jan 14 2026
PRnewswire
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Claim Losses
Jan 14 2026
PRnewswire
Skye Bioscience Faces Class Action for Securities Fraud; Investors Encouraged to Claim
Jan 14 2026
PRnewswire
Show More News
